Janet Woodcock, a top official at the Food and Drug Administration, will retire in 2024 after 37 years of service. Having acted as interim commissioner before Robert Califf took office in 2022, Woodcock was once considered a likely candidate for full-time commissioner. During her tenure, she faced controversy over the approval of opioid painkillers and drugs such as Aduhelm and Exondys.
OIG: OCR should expand scope of HIPAA audit program
The HHS Office of Inspector General (OIG) has called for the Office for Civil Rights (OCR) to expand its HIPAA audit program and define audit
